Common misconceptions

Common mistake
Wrong: Dopamine is the 'happiness' neurotransmitter responsible for the subjective feeling of pleasure.
Right: Dopamine drives reward anticipation and motivation ('wanting'), not the hedonic pleasure of consuming a reward ('liking'), which depends on endogenous opioid signalling.
Dopamine is better understood as the 'wanting' neurotransmitter — it drives motivation, anticipation, and reward-seeking behavior through the mesolimbic pathway. The subjective feeling of pleasure ('liking') is a separate system, tied to endogenous opioid signalling rather than to dopamine. This distinction matters on the MCAT because drugs like cocaine spike dopamine and produce intense craving and compulsive seeking, not simply intense happiness — and questions about addiction are built around this wanting-vs-liking framework.
Common mistake
Wrong: Parkinson's disease involves excess dopamine, while schizophrenia involves dopamine deficiency.
Right: Parkinson's disease involves dopamine deficiency in the nigrostriatal pathway; schizophrenia is associated with excess dopamine activity (especially in mesolimbic pathways).
These are exactly reversed from what many students memorize. Parkinson's disease results from degeneration of dopaminergic neurons in the nigrostriatal pathway, causing dopamine deficiency — hence the motor symptoms like tremor and rigidity. Schizophrenia, by contrast, is associated with excess dopamine activity particularly in mesolimbic pathways, which is why antipsychotic drugs are dopamine antagonists. Mixing these up will get you the wrong answer on any disorder-mechanism question, so anchor it: Parkinson's = low DA (motor pathway); schizophrenia = high DA (limbic pathway).
Common mistake
Wrong: SSRIs relieve depression immediately because they raise serotonin levels right away.
Right: SSRIs block serotonin reuptake immediately, but therapeutic antidepressant effects take 2–4 weeks, likely due to downstream receptor adaptation and neuroplasticity.
SSRIs do raise synaptic serotonin levels almost immediately by blocking the reuptake transporter — but that's not the same as the antidepressant effect. Clinical improvement takes 2–4 weeks because the therapeutic benefit depends on downstream changes: receptor downregulation, neuroplasticity, and possibly hippocampal neurogenesis. The MCAT may test this by describing a patient starting an SSRI and asking what you'd expect — the correct answer acknowledges the delay, not an immediate mood lift.
Common mistake
Wrong: Metabotropic receptors produce faster effects than ionotropic receptors because they activate second-messenger cascades.
Right: Ionotropic receptors (ligand-gated ion channels) produce faster, shorter effects; metabotropic receptors (G-protein coupled) produce slower but more prolonged and widespread effects.
The relationship is the opposite: ionotropic receptors are ligand-gated ion channels, so binding opens the channel directly and ion flux happens in milliseconds — fast but brief. Metabotropic receptors (GPCRs) require G-protein activation and second-messenger cascades, so their effects are slower to start but more prolonged and can affect a wider range of cellular processes. For behavioral pharmacology, this means a drug acting on ionotropic receptors (like benzodiazepines at GABA-A) produces rapid effects, while a drug acting on metabotropic receptors has a delayed but sustained impact.
Guided session

Stuck on this? An AI tutor that probes your understanding and catches where your reasoning breaks.

Start a session →
Free Deck audit

Already run Anki? See if your deck covers this topic.

Upload your deck →

What the exam tests

  1. Map each major neurotransmitter (DA, 5-HT, NE, GABA, Glu, ACh) to its primary behavioral role — knowing, for example, that DA drives reward-seeking and motivation while 5-HT regulates mood and contentment.
  2. Connect neurotransmitter imbalances to specific disorders — dopamine deficiency in Parkinson's vs. dopamine excess in schizophrenia, serotonin dysregulation in depression, GABA/glutamate imbalance in anxiety and seizures, and ACh loss in Alzheimer's disease.
  3. Read a passage describing a drug's mechanism of action (e.g., SSRI, GABA agonist, dopamine antagonist) and predict the resulting behavioral or physiological effect, including side effects.
  4. Distinguish ionotropic from metabotropic receptors and apply that distinction to explain why some drug effects are fast and brief while others are slow and long-lasting.

Can you avoid these mistakes?

A patient is prescribed a drug that blocks dopamine D2 receptors. Based on what you know about dopamine pathways, predict two possible effects — one therapeutic and one adverse — and explain which NT pathway underlies each.
Why does a person addicted to cocaine experience intense craving and compulsive drug-seeking even when they report that the drug no longer makes them feel as good as it once did? Which neurotransmitter system explains this, and how?
A passage describes a novel compound that acts as a positive allosteric modulator at GABA-A receptors (ionotropic). A student predicts the behavioral effect will be slow-onset and prolonged. Are they correct? Explain the time course you'd actually expect and why.
A clinician starts a patient on an SSRI on Monday. By Wednesday, the patient calls to say they don't feel better yet. Is this expected? Explain the difference between the drug's immediate synaptic mechanism and when you'd expect clinical antidepressant effects to appear.

Related topics

Find out what you actually understand about this topic — a tutor that probes your reasoning and catches where it breaks.

Start a session →

Already run Anki? Get a free deck audit →